| Status: Recommended |
Everolimus (Votubia®) is recommended for use within NHS Wales for the treatment of:
- adult patients with renal angiomyolipoma associated with tuberous sclerosis complex who are at risk of complications (based on factors such as tumour size or presence of aneurysm, or presence of multiple or bilateral tumours) but who do not require immediate surgery, and;
- patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex who require therapeutic intervention but are not amenable to surgery
This recommendation applies only in circumstances where the approved Patient Access Scheme (PAS) is utilised or where the list/contract price is equivalent to or lower than the PAS price. |
|
|
Medicine details
|
| Medicine name |
everolimus (Votubia®) |
| Formulation |
1 mg, 2 mg, 3 mg and 5 mg dispersible tablets; 2.5 mg, 5 mg and 10 mg tablets |
| Reference number |
1156 |
| Indication |
- Treatment of adult and paediatric patients with subependymal giant cell astrocytoma (SEGA) associated with TSC who require therapeutic intervention but are not amenable to surgery (tablets and dispersible tablets)
- Treatment of adult patients with renal angiomyolipoma associated with TSC who are at risk of complications (based on factors such as tumour size or presence of aneurysm, or presence of multiple or bilateral tumours) but who do not require immediate surgery (tablets).
|
| Company |
Novartis Pharmaceuticals UK Ltd |
| BNF chapter |
Central nervous system |
| Submission type |
N/A |
| Status |
Recommended |
| Advice number |
2322 |
| AWMSG meeting date |
06/12/2022 |
| Date of issue |
08/12/2022 |
| Commercial arrangement |
PAS |
Further information
See also the AWMSG recommendation for the use of everolimus (Votubia®) for the adjunctive treatment of patients aged 2 years and older whose refractory partial-onset seizures, with or without secondary generalisation, are associated with tuberous sclerosis complex (TSC). |